home / stock / allo / allo quote
Last: | $2.89 |
---|---|
Change Percent: | -0.71% |
Open: | $2.85 |
Close: | $2.89 |
High: | $2.92 |
Low: | $2.73 |
Volume: | 2,096,493 |
Last Trade Date Time: | 07/22/2024 03:00:00 am |
Quotes are delayed by 15 to 20 minutes.
Last | Open | Close | High | Low | Volume | Date |
---|---|---|---|---|---|---|
$2.89 | $2.85 | $2.89 | $2.92 | $2.73 | 2,096,493 | 07-22-2024 |
$2.83 | $3.07 | $2.83 | $3.07 | $2.805 | 2,233,657 | 07-19-2024 |
$3.05 | $3.38 | $3.05 | $3.5 | $2.91 | 4,728,850 | 07-18-2024 |
$3.42 | $3.44 | $3.42 | $3.5 | $3.2888 | 4,024,547 | 07-17-2024 |
$3.5 | $3 | $3.5 | $3.67 | $3 | 8,958,367 | 07-16-2024 |
$2.98 | $2.78 | $2.98 | $3.1 | $2.74 | 3,646,757 | 07-15-2024 |
$2.76 | $2.7 | $2.76 | $2.85 | $2.66 | 1,734,421 | 07-12-2024 |
$2.68 | $2.53 | $2.68 | $2.73 | $2.465 | 3,178,478 | 07-11-2024 |
$2.39 | $2.3 | $2.39 | $2.4 | $2.275 | 1,376,673 | 07-10-2024 |
$2.3 | $2.22 | $2.3 | $2.32 | $2.195 | 2,820,614 | 07-09-2024 |
$2.24 | $2.19 | $2.24 | $2.29 | $2.13 | 2,062,393 | 07-08-2024 |
$2.12 | $2.1 | $2.12 | $2.13 | $2.01 | 2,298,847 | 07-05-2024 |
$2.08 | $2.2 | $2.08 | $2.2 | $2.08 | 1,775,732 | 07-04-2024 |
$2.08 | $2.2 | $2.08 | $2.2 | $2.08 | 1,775,732 | 07-03-2024 |
$2.16 | $2.29 | $2.16 | $2.29 | $2.125 | 3,053,360 | 07-02-2024 |
$2.33 | $2.33 | $2.33 | $2.41 | $2.3 | 2,245,996 | 07-01-2024 |
$2.33 | $2.44 | $2.33 | $2.445 | $2.27 | 3,585,124 | 06-28-2024 |
$2.44 | $2.34 | $2.44 | $2.495 | $2.28 | 2,371,575 | 06-27-2024 |
$2.34 | $2.39 | $2.34 | $2.4392 | $2.23 | 2,996,283 | 06-26-2024 |
$2.4 | $2.6 | $2.4 | $2.6 | $2.39 | 3,973,965 | 06-25-2024 |
News, Short Squeeze, Breakout and More Instantly...
Allogene Therapeutics Inc. Company Name:
ALLO Stock Symbol:
NASDAQ Market:
Allogene Therapeutics Inc. Website:
Patient Screening is Underway at Rocky Mountain Cancer Centers, Part of the US Oncology Network and Sarah Cannon Research Institute; Astera Cancer Care, Part of the OneOncology Network; and Norton Cancer Institute ALPHA3 Will be the First Pivotal Trial to Offer CAR T as Part of First Line (...
SOUTH SAN FRANCISCO, Calif., May 23, 2024 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) products for cancer and autoimmune disease, today announced it will participate in th...
SOUTH SAN FRANCISCO, Calif., May 13, 2024 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) products for cancer and autoimmune disease, today announced the pricing of an underwr...